Biosimilars are identified by two stable signals: a product-specific HCPCS Q-code assigned by CMS (for example Q5117 for Kanjinti, Q5121 for Avsola, Q5127 for Stimufend) and an FDA-assigned four-letter suffix appended to the reference product's non-proprietary name (for example trastuzumab-anns, infliximab-axxq, pegfilgrastim-fpgk). The Q-code goes on the claim line; the suffix lives on the FDA label and in the FDA Purple Book and is how clinical and pharmacovigilance systems trace the product. There is no CMS HCPCS modifier whose purpose is to flag a drug as a biosimilar. The “JR” modifier that occasionally shows up in claim files is not a real CMS modifier — strip it.
The regulatory authority for biosimilar non-proprietary naming is the FDA. In January 2017, FDA finalized its Guidance for Industry: Nonproprietary Naming of Biological Products, which established the convention that each biosimilar receives a non-proprietary name composed of the reference product's core proper name plus a hyphenated four-letter suffix randomly assigned by FDA. The suffix is intentionally devoid of meaning; it exists to support adverse-event tracking, distinguish products in pharmacy systems, and prevent inadvertent substitution at the dispensing level. The FDA Purple Book is the authoritative public source for the current mapping of suffix to brand to reference product to license number.
On the claims side, CMS assigns each FDA-approved biosimilar its own HCPCS code through the quarterly HCPCS coding cycle. The vast majority of biosimilars are coded with a Q-series HCPCS (Q5103, Q5104, Q5117, Q5121, and so on); a small number have been issued J-codes when product format or distribution warranted (Zymfentra, the subcutaneous infliximab biosimilar, is coded J1748). The Q-code or J-code on the claim line carries the product identity. No modifier appendage is required, and no CMS HCPCS modifier exists whose definition is “this is a biosimilar.”
The combination of FDA-assigned non-proprietary name suffix and CMS-assigned Q-code is the system that the entire biosimilar billing apparatus rests on. The convention is stable across all major payers: Medicare Part B, Medicare Advantage, and commercial plans all key on the Q-code, not on any modifier, to determine which biosimilar was administered.
The convention applies every time a biosimilar is billed, regardless of payer. The variation across payers is in which biosimilar is preferred (driven by UnitedHealthcare and Aetna biosimilar substitution mandates and the Accredo / Express Scripts and CenterWell Specialty preferred-product lists), not in how the chosen biosimilar gets identified on the claim. The Q-code does the identification work.
The four families below cover the bulk of biosimilar billing volume on the specialty drug pages in this catalog. For each, the reference product J-code is shown alongside the biosimilars currently in active billing use with their Q-codes and FDA non-proprietary names.
| Family | Reference (J-code) | Biosimilars (Q-code — non-proprietary name) |
|---|---|---|
| Trastuzumab (Herceptin family) | Herceptin — J9355 | Ogivri Q5114 (trastuzumab-dkst); Herzuma Q5113 (trastuzumab-pkrb); Ontruzant Q5112 (trastuzumab-dttb); Trazimera Q5116 (trastuzumab-qyyp); Kanjinti Q5117 (trastuzumab-anns); Hercessi Q5144 (trastuzumab-strf) |
| Infliximab (Remicade family) | Remicade — J1745 | Inflectra Q5103 (infliximab-dyyb); Renflexis Q5104 (infliximab-abda); Avsola Q5121 (infliximab-axxq); Zymfentra J1748 (infliximab-dyyb, subcutaneous formulation) |
| Pegfilgrastim (Neulasta family) | Neulasta — J2506 | Fulphila Q5108; Udenyca Q5111; Ziextenzo Q5120 (pegfilgrastim-bmez); Nyvepria Q5122 (pegfilgrastim-apgf); Stimufend Q5127 (pegfilgrastim-fpgk — 0.5 mg unit basis); Fylnetra Q5130 (pegfilgrastim-pbbk) |
| Tocilizumab (Actemra family) | Actemra — J3262 | Tofidence Q5133 (tocilizumab-bavi); Tyenne Q5135 (tocilizumab-aazg); Avtozma Q5156 (tocilizumab-anoh) |
The unit basis caveat on Stimufend (Q5127, 0.5 mg per unit) is the single most common arithmetic error in the pegfilgrastim family: a 6 mg administered dose is 12 billing units of Q5127, not 6. Always read the long descriptor on the active HCPCS quarterly file rather than assuming the unit basis from the family.
The single largest source of biosimilar denials is HCPCS-code mismatch — the reference product code billed when a biosimilar was dispensed, or one biosimilar's Q-code billed when a different biosimilar in the same family was actually administered. Build the dispensing-record-to-Q-code lookup into the claim build, and audit a sample of biosimilar claims quarterly against the dispensing records to catch drift between the PA-approved product and the product actually billed.
All major payers — Medicare Part B, Medicare Advantage, and the major commercials — require the product-specific HCPCS code matching the actual biosimilar dispensed. None require any “biosimilar modifier.” The variation across payers is in which biosimilar is preferred (driven by formulary and biosimilar-substitution mandates), not in how the chosen biosimilar gets identified on the claim line.
| Payer | Biosimilar billing convention | Notes |
|---|---|---|
| Medicare (Part B) | Q-code matching the dispensed product; no biosimilar modifier | Source-of-truth payer. ASP pricing files publish per-Q-code rates. JW/JZ apply for single-dose vial waste. JG (most provider types) or TB (rural / sole-community / critical-access in covered scenarios) apply for 340B acquisition. MACs may issue LCDs preferring specific biosimilars in certain indications, but the billing convention — Q-code on the line, no biosimilar modifier — is consistent across jurisdictions. |
| UnitedHealthcare | Q-code matching the dispensed product; no biosimilar modifier | UHC operates an active biosimilar substitution mandate on the medical benefit, driving prior authorizations toward preferred biosimilars in trastuzumab, infliximab, and pegfilgrastim families. The mandate is enforced at the PA stage; on the claim line itself, the requirement is the same as Medicare — report the Q-code for the actually-dispensed product. OptumRx infused-meds management workflows key on the Q-code, not on any modifier. |
| Aetna (CVS Health) | Q-code matching the dispensed product; no biosimilar modifier | Aetna operates a biosimilar substitution mandate parallel to UHC's, with preferred biosimilars specified in medical-policy bulletins by indication. CVS Specialty dispensing reports include the brand name, NDC, and HCPCS code of the dispensed biosimilar; reconcile the claim against the CVS Specialty report rather than the original prescriber order. |
| Cigna / Express Scripts | Q-code matching the dispensed product; no biosimilar modifier | Cigna commercial and Accredo network claims follow the same Q-code-by-product convention. Accredo's preferred-biosimilar formulary determines which product gets dispensed; the dispensing report carries the dispensed product's HCPCS code. The buy-and-bill claim must match. |
| Humana | Q-code matching the dispensed product; no biosimilar modifier | MA-heavy book follows CMS biosimilar billing convention by default. CenterWell Specialty preferred-biosimilar dispensing carries the appropriate Q-code on the dispensing record. Humana commercial follows the same pattern with a slightly different preferred-product list per indication. |
The consistent rule across payers: the Q-code is the product identity, the PA decides which Q-code applies, and the dispensing record is the authoritative source for confirming which Q-code to bill. No payer keys biosimilar adjudication off a modifier.
| Denial pattern | What it means | Fix / appeal language |
|---|---|---|
| Reference J-code billed when biosimilar dispensed (mismatch) | The claim line carries J9355 (Herceptin), J1745 (Remicade), J2506 (Neulasta), or J3262 (Actemra) when the actual product dispensed was a biosimilar with its own Q-code (e.g., Q5117 Kanjinti, Q5121 Avsola, Q5127 Stimufend, Q5133 Tofidence). Payer adjudication mismatches the HCPCS against the PA-approved or formulary-preferred product. | Resubmit with the correct Q-code matching the dispensed product. Appeal language: “The product actually dispensed and administered was [biosimilar brand], NDC [X], FDA non-proprietary name [reference-name-suffix], reportable under HCPCS [Q-code]. The corrected claim uses the product-specific Q-code in place of the reference brand J-code. JW/JZ reporting rules per CMS IOM Pub 100-04 Chapter 17 §40 are unchanged.” |
| Fictional “JR” modifier on the line (silent ignore or audit flag) | JR is not a CMS HCPCS modifier. It does not appear in the modifier file. Payers typically silently ignore it at adjudication, but it sits in the claim record as audit-trail noise and is sometimes flagged by post-payment audit programs. | Strip JR from the claim and from the vendor template that inserted it. Audit-trail note: “Removed JR modifier — JR is not a valid HCPCS Level II modifier per the CMS modifier file. Biosimilar product identity is conveyed by the Q-code on the line.” |
| JG appended on biosimilar claim (correct if 340B, wrong if treated as “biosimilar modifier”) | JG is the 340B-acquisition modifier under Medicare Part B and is correctly appended when the drug was acquired through the 340B program. It is sometimes misused as if it were a “biosimilar modifier,” appended on biosimilar lines for non-340B claims. | If the drug was 340B-acquired, JG is correct — keep it. If the drug was not 340B-acquired, strip JG from the line. Appeal language for the non-340B case: “The drug was not 340B-acquired; JG is removed from the corrected claim. Biosimilar identity is conveyed by the Q-code on the line; no biosimilar modifier exists in CMS HCPCS.” |
| Wrong unit count on biosimilar line (unit-basis error) | Common in the pegfilgrastim family: a 6 mg dose of Stimufend (Q5127, 0.5 mg unit basis) billed as 6 units instead of 12. The HCPCS long descriptor's unit basis was misread. | Recompute billing units against the active HCPCS quarterly file's long descriptor for the Q-code. Resubmit with corrected unit count. Appeal language: “The corrected claim reports [N] billing units of [Q-code] computed against the unit basis of [X] mg per unit specified in the HCPCS long descriptor. Total milligrams administered ([dose]) matches the dispensing record.” |
| Reference-product NDC paired with biosimilar Q-code | The HCPCS Q-code on the line is the biosimilar, but the NDC supplied is the reference product. Payer cross-validation flags the inconsistency. | Resubmit with the NDC of the actually-dispensed biosimilar product matching its Q-code. Reconcile against the dispensing record or pharmacy invoice. Appeal language: “The corrected claim pairs HCPCS [Q-code] with NDC [biosimilar NDC] matching the actually-dispensed product per the dispensing record.” |
| Biosimilar substitution dispute (PA approved different biosimilar than was dispensed) | UHC, Aetna, or other payer biosimilar-mandate prior authorization approved one preferred biosimilar, but the dispensed and billed product was a different biosimilar in the same family. Adjudication denies as not-PA-approved. | Either rework the claim to match the PA-approved Q-code (if the dispensed product was an error) or appeal with documentation that the dispensed product was clinically necessary and meets the payer's substitution exception criteria. Appeal language: “The product actually dispensed was [biosimilar brand], Q-code [Q-code], per [reason — supply availability, prior intolerance, etc.]. Per [payer policy bulletin] substitution exception criteria, the corrected claim reports the dispensed product's Q-code with supporting documentation attached.” |
No. There is no CMS HCPCS modifier whose purpose is to flag a drug as a biosimilar. Biosimilars are identified on a claim by the product-specific HCPCS code (almost always a Q-code, e.g., Q5117 for Kanjinti) and, in clinical and FDA contexts, by the four-letter non-proprietary name suffix assigned by FDA (e.g., trastuzumab-anns). The Q-code itself carries the product identity; no modifier appendage is required or available to convey “this is a biosimilar.”
JR is not a real CMS HCPCS modifier. It does not appear in the CMS HCPCS Level II modifier file. When “JR” surfaces in a claim file it is almost always one of three things: a data-entry error, a vendor-system field misuse, or a copy-paste artifact from a non-CMS internal flag at a specific payer. Strip it from current claims. The intended meaning — “this line was a biosimilar” — is already carried by the product-specific Q-code and does not need a modifier.
Match the actual product dispensed against the CMS HCPCS quarterly file. Each biosimilar has its own Q-code (Kanjinti is Q5117, Hercessi is Q5144, Inflectra is Q5103, Avsola is Q5121, Stimufend is Q5127, and so on). The Q-code, brand name, and FDA-assigned four-letter suffix on the non-proprietary name are a stable triple that identifies the product. Confirm against the dispensing record or pharmacy invoice on every claim — substituting the reference product J-code (e.g., J9355 for Herceptin) for a biosimilar Q-code is a mismatch denial.
From the FDA. The FDA finalized its guidance on Nonproprietary Naming of Biological Products in 2017. Under that guidance each biosimilar receives a non-proprietary name composed of the reference product's core proper name (e.g., trastuzumab, infliximab, pegfilgrastim) plus a four-letter suffix that is randomly assigned by FDA and devoid of meaning. The suffix exists to support pharmacovigilance and product traceability, not to encode characteristics of the product. The authoritative source for the current suffix-to-brand mapping is the FDA Purple Book.
No. The HCPCS code on the claim line must match the product actually dispensed and administered. Billing J9355 (Herceptin reference) when the patient received Kanjinti (Q5117) is a mismatch denial and an audit-trail problem. The same rule applies to all of the major biosimilar families: infliximab biosimilars must report their Q-code (Q5103 Inflectra, Q5104 Renflexis, Q5121 Avsola) rather than J1745 Remicade; trastuzumab biosimilars must report their Q-code rather than J9355; pegfilgrastim biosimilars must report their Q-code rather than J2506; tocilizumab biosimilars must report their Q-code rather than J3262.
Identically to reference-product J-codes. If the biosimilar is supplied in a single-dose container and drug was discarded, report the administered units on one line (no waste modifier) and the discarded units on a second line with the biosimilar Q-code and the JW modifier. If no drug was discarded, report a single line with the Q-code and the JZ modifier appended. The waste-reporting convention does not change between reference and biosimilar — only the base HCPCS code changes.
An FDA interchangeability designation is a substitution-level regulatory determination, not a billing instruction. Interchangeable biosimilars can in some states be substituted at the pharmacy level without prescriber involvement, but on the medical-benefit billing side the rule is unchanged: bill the Q-code for the product actually dispensed and administered. Interchangeability does not introduce a new modifier and does not let you bill the reference product J-code for an interchangeable biosimilar.
Both UnitedHealthcare and Aetna operate biosimilar substitution mandates on the medical benefit, and Cigna's Accredo and Express Scripts apply preferred-biosimilar formulary policies. These mandates determine which biosimilar is preferred for a given indication; they do not change the billing convention. On every covered claim you still report the Q-code for the product actually dispensed, with JW/JZ as applicable for single-dose vial waste and JG/TB as applicable for 340B. The mandates surface upstream of billing in the prior-authorization decision; if the PA approved a biosimilar, dispensing and billing must match that biosimilar's Q-code.
All sources are publicly available federal publications or paraphrased from trade-association educational materials and publicly available payer policy bulletins. The methodology by which we resolve source disagreements is described in the Methodology.